Abstracts tagged "glucocorticoids"

Abstract Number: 1428 • ACR Convergence 2021
Association Between Ongoing Glucocorticoid Use and Major Adverse Cardiovascular Events Among Veterans with Rheumatoid Arthritis
Beth Wallace¹, Yuqing Gao², Punyasha Roul³, Shirley Cohen-Mekelberg², Bryant England³, Ted Mikuls³, Daniel Clauw⁴, Wyndy Wiitala², Rodney Hayward⁵, Jeremy Sussman⁶ and Akbar Waljee⁵, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Michigan, VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, ⁶University of Michigan; VA Ann Arbor Healthcare System; Center for Clinical Management Research, Ann Arbor, MI
Background/Purpose: A third of RA patients use long-term glucocorticoids (GCs) despite a known dose-dependent association with major adverse cardiovascular (CV) events (MACE). Prior work suggests…
Abstract Number: 0089 • ACR Convergence 2020
The Risk Factors of Recurrence in Relapsing Polychondritis; A Study of 41 Cases
Tsuneyasu Yoshida¹, Hajime Yoshifuji², Mirei Shirakashi¹, Koji Kitagori¹, Shuji Akizuki², Ran Nakashima¹, Kosaku Murakami¹, Motomu Hashimoto³, Masao Tanaka³ and Koichiro Ohmura¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan
Background/Purpose: Relapsing polychondritis (RP) is a rare disease which causes inflammation in systemic cartilages. Although glucocorticoids (GC) and immunosuppressive drugs (IS) have been used, the…
Abstract Number: 1442 • ACR Convergence 2020
Denosumab versus Oral Bisphosphonate for Osteoporosis in Long-term Glucocorticoid Users: A 12-month Randomized Controlled Trial
Chi Chiu Mok¹, Ling Yin Ho¹ and Kwok Man Ma¹, ¹Tuen Mun Hospital, Hong Kong, China (People's Republic)
Background/Purpose: To compare the efficacy of denosumab (DEN) and oral alendronate (ALN) on spinal bone mineral density (BMD) in long-term glucocorticoid users.Methods: Patients receiving long-term…
Abstract Number: 0109 • ACR Convergence 2020
Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Eileen Rife¹, Emejuaiwe Nkechinyere² and Jose Leon de la Rocha³, ¹Louisiana State University, Metairie, LA, ²Department of Veterans Affairs, New Orleans, LA, ³Louisiana State University, Auburn, AL
Background/Purpose: Descriptive study designed to assess compliance to evidence-based practice guidelines for the prevention of Glucocorticoid-Induced Osteoporosis (GIOP).Methods: We queried the electronic database of the…
Abstract Number: 1590 • ACR Convergence 2020
Bone Health in ANCA – Associated Vasculitis Patients
Deepa Ragesh Panikkath¹, Sandy Lee² and Christina Downey², ¹Loma Linda University Health, Department of Rheumatology, Loma Linda, CA, ²Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Glucocorticoids (GC) are an important mode of therapy in ANCA associated vasculitis (AAV), and osteoporosis (OP) and fractures are potential adverse effects seen. The…
Abstract Number: 0120 • ACR Convergence 2020
Risk of Fracture in Patients with Different Glucocorticoid Requiring Diseases
Giovanni Adami¹, Angelo Fassio², Alessandro Giollo², Luca Idolazzi², Ombretta Viapiana¹, Davide Gatti² and Maurizio Rossini², ¹University of Verona, Verona, Italy, ²Rheumatology Unit, University of Verona, Verona, Italy
Background/Purpose: The aim of the present work is to determine the fracture risk associated with glucocorticoids requiring diseasesMethods: We conducted a retrospective analysis of a nation-wide…
Abstract Number: 1739 • ACR Convergence 2020
Patients with Early Rheumatoid Arthritis Considered to Have a Favourable Risk Profile and Treated According to a Step-up Strategy Have an Increased Risk of Chronic Analgesic Consumption
Sofia Pazmino¹, Annelies Boonen², Diederik De Cock¹, Veerle Stouten¹, Delphine Bertrand¹, Johan Joly³, Rene Westhovens⁴ and Patrick Verschueren⁵, ¹KU Leuven, Leuven, Belgium, ²Maastricht University Medical Center, Maastricht, Netherlands, ³University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium, ⁴University Hospitals Leuven, Belgium, Leuven, Belgium, ⁵University Hospital Leuven, Leuven, Belgium
Background/Purpose: Pain remains the highest priority for improvement to patients with Rheumatoid Arthritis (RA). Analgesic prescription in RA was historically a stand-alone approach and afterwards…
Abstract Number: 0126 • ACR Convergence 2020
Immunophenotyping of Peripheral Blood Highlights an Association of Dysregulated Lymphocytes with Patients with Glucocorticoid-induced Osteonecrosis
Kaichi Kaneko¹, Hao Chen¹, Alexandra Krez², Steven Zeng¹, Peter Park¹, Ye-Ji Lee¹, Takayuki Fujii¹, Haemin Kim¹, Sehwan Mun¹, Seyeon Bae¹, Tania Pannellini³, Joseph Lane⁴, Derek Hansen⁴, Douglas Mintz⁵, Richard Bockman², Emily Stein⁶ and Kyung-Hyun Park-Min⁷, ¹Arthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ²Endocrine Service, Hospital for special surgery, New York, NY, ³Pathology and Precision Medicine Laboratory, Hospital for special surgery, New York, NY, ⁴Orthopedic surgery, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY, ⁵Radiology, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY, ⁶Endocrine Service, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY, ⁷Arthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, Department of Medicine, Weill Cornell Medical College, New York, NY
Background/Purpose: Avascular necrosis (AVN) is a musculoskeletal condition that can result in significant pain and compromised quality of life. The diverse etiologies of AVN have…
Abstract Number: 1743 • ACR Convergence 2020
Perioperative Steroids in Rheumatoid Arthritis Patients Having Total Joint Replacements: Help or Harm?
Tariq Chukir¹, Susan Goodman², Haley Tornberg³, Huong Do⁴, Charlene Thomas⁵, Alana Sigmund³, Peter Sculco⁶, Bella Mehta⁶, Linda Russell⁶, Mark Figgie² and Emily Stein⁷, ¹Weill Cornell Medicine and New York Presbyterian Hospital, New York, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, ⁴Hospital for Special Surgery, New York, NY, ⁵Weill Cornell Medicine, New York, ⁶Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁷Endocrine Service, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY
Background/Purpose: Optimal perioperative glucocorticoids (GC) dosing for rheumatoid arthritis (RA) patients on chronic GCs undergoing total joint replacement is unknown. Ideal GC dosing prevents perioperative…
Abstract Number: 0132 • ACR Convergence 2020
Prevalence of Osteoporosis and Fragitlity Fractures Is Not Different Between ACPA Positive Patients Compared to ACPA Negative Patients in a Real World Setting, Despite Longer Disease Duration and Glucocorticoid-Treatment
Edgar Wiebe¹, Desiree Freier¹, Dörte Huscher², Gloria Dallagiacoma³, Sandra Hermann¹, Robert Biesen⁴, Gerd Burmester⁵ and Frank Buttgereit⁶, ¹Charité University Medicine Berlin, Dep. of Rheumatology and Clinical Immunology, Berlin, Germany, ²Charité University Medicine Berlin, Dep. of Biometry and Clinical Epidemiology, Berlin, Germany, ³University of Verona, Dep. of Rheumatology, Verona, Italy, ⁴Charité University Medicine, Dep. of Rheumatology and Clinical Immunology, Berlin, ⁵Charité University Hospital Berlin, Berlin, Germany, ⁶Charité University Medicine, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased systemic bone loss, leading to a high risk for hip, vertebral and non-hip, non-vertebral fractures. Especially ACPA…
Abstract Number: 1751 • ACR Convergence 2020
Forecasting Healthcare Utilization in Rheumatoid Arthritis: A Machine Learning Predictive Model of Emergency Department Visits and Prednisone Initiation in a Single Tertiary Academic Center
Elston He¹, Eli Cornblath², Pratyusha Yalamanchi³, Alexis Ogdie², Joshua Baker² and Michael George², ¹Synovium, Inc., Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Michigan Medicine, Ann Arbor, MI
Background/Purpose: Despite recent advances in therapy, 42% of patients with rheumatoid arthritis (RA) nationwide had moderate or high disease activity at their most recent visit.…
Abstract Number: 0219 • ACR Convergence 2020
Is It Realistic to Stop Prednisone in Early Rheumatoid Arthritis? A Subanalysis from the BeSt and IMPROVED Studies
Raquel Dos-Santos¹, Sytske Anne Bergstra², J. M. Maassen², Thomas Huizinga² and CF Allaart², ¹Clinical University Hospital in Santiago de Compostela, Santiago de Compostela, Galicia, Spain, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Glucocorticoids are widely used in the treatment of rheumatoid arthritis (RA) patients. It is internationally recommended to taper and stop glucocorticoids as rapidly as…
Abstract Number: 1827 • ACR Convergence 2020
Flare Reduction and Oral Corticosteroid Taper in Patients with Active SLE Treated with Anifrolumab in 2 Phase 3 Trials
Richard Furie¹, Eric Morand², Anca Askanase³, Ed Vital⁴, Joan Merrill⁵, Rubana Kalyani⁶, Gabriel Abreu⁷, Lilia Pineda⁶ and Raj Tummala⁶, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, ²Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ³Columbia University College of Physicians and Surgeons, New York, ⁴University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Objectives of long-term SLE management are not only to reduce disease activity, but also to prevent flares and minimize exposure to oral corticosteroids (OCS),…
Abstract Number: 0220 • ACR Convergence 2020
Impact of Concomitant Glucocorticoids on the Clinical Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: An Ad Hoc Analysis of Data from Three Phase 3 Studies
Bernard Combe¹, Frank Buttgereit², Andrew Östör³, Ricardo Xavier⁴, Alain Saraux⁵, Capucine Daridon⁶, Kirsten Famulla⁷, Yanna Song⁸, Ivan Lagunes-Galindo⁹ and Gerd Burmester¹⁰, ¹University of Montpellier, Montpellier, France, ²Charité University Medicine, Berlin, Germany, ³Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, ⁴Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Rio Grande do Sul, Brazil, ⁵Department of Rheumatology, UBO, CHU, INSERM 1227 (LBAI), Brest, France, ⁶AbbVie France, Rungis, France, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie Inc., North Chicago,, IL, ⁹AbbVie Inc., North Chicago, IL, ¹⁰Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: Glucocorticoid (GC) therapy has strong anti-inflammatory effects and helps slow radiographic progression in RA1; however, GCs can be associated with adverse events (AEs) such…
Abstract Number: 1828 • ACR Convergence 2020
Comprehensive Efficacy of Anifrolumab Across Organ Domains in Patients with Active SLE: Pooled Data from 2 Phase 3 Trials
Eric Morand¹, Richard Furie², Ian Bruce³, Ed Vital⁴, Maria Dall'Era⁵, Emmanuelle Maho⁶, Lilia Pineda⁷ and Raj Tummala⁷, ¹Monash University, Melbourne, Australia, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, ³Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Division of Rheumatology, University of California, San Francisco, CA, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁷BioPharmaceuticals R&D, AstraZeneca, Gaithersburg
Background/Purpose: SLE is a heterogeneous autoimmune disease with clinical manifestations across multiple organ systems. In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab treatment resulted…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].